Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Temsirolimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 8/20 | 0.84 |
| ▸ | MTOR | P42345 | 8/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.85 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.85 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.85 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temsirolimus SCHEMBL14655780 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL12731651 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL16848395 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL799689 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL13610010 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL18931150 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL16848394 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL19666839 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL21960607 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL18792 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2014-02-06 | — | — | US | disclosed |
| US-8524893-B2 | Process for the preparation of temsirolimus and its intermediates | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2013-09-03 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012120048-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | FONDAZIONE TELETHON (IT) | 2012-09-13 | — | — | WO | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110301189-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF RAPAMYCIN ESTERS | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2011-12-08 | — | — | US | disclosed |
| US-20110184167-A1 | PROCESS FOR THE PREPARATION OF TEMSIROLIMUS AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | FKBP1A 3006/4885MTOR 2908/4885ABCC3 4500/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | FKBP1A 2639/4885MTOR 4823/4885ABCC3 3954/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | FKBP1A 1717/4885MTOR 1805/4885ABCC3 3731/4885 |
| US-20140038920-A1 | TFEB PHOSPHORYLATION INHIBITORS AND USES THEREOF | TFEB, SQSTM1, ULK1 | FKBP1A 2105/4885MTOR 8/4885ABCC3 3827/4885 |
| US-20110301189-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF RAPAMYCIN ESTERS | RICTOR, MTOR, RPTOR | FKBP1A 76/4885MTOR 2/4885ABCC3 3262/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | FKBP1A 2639/4885MTOR 4823/4885ABCC3 3954/4885 |
| US-20110184167-A1 | PROCESS FOR THE PREPARATION OF TEMSIROLIMUS AND ITS INTERMEDIATES | RICTOR, MTOR, MAPKAP1 | FKBP1A 226/4885MTOR 2/4885ABCC3 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.